EFFECT OF IVIG DOSE ON ANTI-AMYLOID BETA ANTIBODY AND AMYLOID BETA PEPTIDE BLOOD

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The present study examines the pharmacokinetics, safety and therapeutic effects of passive immunization with intravenous immunoglobulin (IVIg) in patients with mild to moderate Alzheimer's (AD). The hypothesis of this Phase I study is that the administration of IVIg (Gammagard S/D, manufactured by Baxter) to patients with mild to moderate Alzheimer's Disease (AD) will increase the level of anti-amyloid beta peptide antibodies and amyloid beta peptide in their blood. The specific aim is to investigate the pharmacokinetic response to IVIg administration performed at varied doses and intervals in 8 subjects.